BioSpace News Archive

As Americans continue to seek safe ways to return to work, school, and in-person events during the COVID-19 pandemic, 7Factor Software recently announced the addition of vaccine tracking to WellEntry, its popular infectious disease screening solution.

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Bill Newell , Chief Executive Officer, will participate in the Ovarian Cancer Panel discussion on March 2, 2021

Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced the addition of three seasoned pharmaceutical leaders, Kathy He , Richard Lee , MD, and Dana Zhang , MD, to its expanding team.

First FDA-Approved OTC Preservative-Free Antihistamine Eye Drop Approved for Relief of Itchy Eyes Associated with Allergies Now Rolling out to Major U.S. Retailers

MaxCyte, Inc., a global cell-based therapies and life sciences company, today announced two upcoming presentations at virtual healthcare investor conferences. Details are as follows.

Blackfynn, a company using a systematic approach that combines data, technology and disease-specific clinical expertise to develop a growing pipeline of targeted, clinical-stage therapeutics for Parkinson’s and neurodegeneration, announced that Stephen Hahn, M.D. will join its Board of Directors.

Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced that Adam Dinerman, Ph.D. and John Liu, Ph.D. have joined the company as Executive Director, Head of Chemistry, Manufacturing and Controls (CMC) and Vice President, Biology, respectively.

Bristol Myers Squibb to Participate in Raymond James Virtual 42 nd Annual Institutional Investors Conference

Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, announced today that it has launched its new Glaucoma Module feature for the Harmony Clinical Data Management Solution.

Exclusive license agreement broadens Day One’s clinical-stage pipeline of targeted cancer therapies with the additions of pimasertib and MSC2015103B Day One plans to evaluate the combination of pimasertib and DAY101, the Company’s clinical-stage pan-RAF kinase inhibitor, in patients ≥12 years of age with advanced solid tumors